Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old

NCT05643534 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT05643534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05643534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
Lead sponsor
Ardelyx
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2022
Completion date
August 20, 2026
Enrollment
180 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with constipation (ibs-c)